Allergan, an AbbVie company, Madison, New Jersey, and Irvine, California.
Endpoint Outcomes, Boston, Massachusetts, and Long Beach, California.
Optom Vis Sci. 2022 Aug 1;99(8):635-644. doi: 10.1097/OPX.0000000000001913. Epub 2022 Jun 9.
Presbyopia typically occurs around 40 years of age and affects approximately one-quarter of the global population. Up to October 2021, there were no approved pharmacotherapies for presbyopia, and common treatments, such as glasses, can have disadvantages for individuals' health-related quality of life.
This study aimed to document the experience of living with and managing presbyopia, identify perspectives on treatment options, and determine whether there is an unmet need in the treatment landscape.
Coded transcripts of concept elicitation (CE; n = 20) and cognitive debriefing (n = 20) interviews with presbyopic individuals, originally conducted for development of patient-reported outcome instruments, were reanalyzed to identify salient concepts describing participants' experiences with presbyopia treatments. Qualitative ranking exercises assessed participants' preferences for a potential pharmacotherapy vs. existing treatments.
Because most concepts were identified with the CE interviews, data reflect CE findings unless otherwise noted. Average age across CE/cognitive debriefing interviews was 49.4 years; a vast majority of participants used glasses for presbyopia treatment. Four themes related to treatment with glasses were identified with the interviews: inconvenience during daily activities, negative physical sensations around the eyes/head, limitations, and undesirable impacts on daily life (e.g., psychosocial). Most commonly, participants reported inconveniences related to forgetting glasses and psychosocial impacts (e.g., feeling/looking older). Strained/tired eyes and limited ability to see at varying distances were also reported. Among participants with near-vision glasses who provided data, two-thirds expressed interest in alternative treatments. In addition, almost three-quarters of the participants ranked hypothetical eye drops as their first or second preferred option, vs. reading glasses, contact lenses, magnifying glasses, and surgery.
This study explored the experience of living with and managing presbyopia and identified limitations and negative impacts of current treatments. Pharmacological development (e.g., eye drops) may fulfill an unmet need in the presbyopia treatment landscape.
老花眼通常发生在 40 岁左右，影响了全球约四分之一的人口。截至 2021 年 10 月，尚无针对老花眼的批准的药物疗法，而常见的治疗方法，如眼镜，可能会对个人的健康相关生活质量产生不利影响。
本研究旨在记录与老花眼共存和管理的经验，确定对治疗选择的看法，并确定治疗领域是否存在未满足的需求。
对与老花眼患者进行的概念发掘（CE；n=20）和认知性深入访谈（n=20）的编码转录本进行重新分析，以识别描述参与者老花眼治疗经验的重要概念。定性排名练习评估了参与者对潜在药物治疗与现有治疗的偏好。
由于大多数概念都是通过 CE 访谈确定的，因此除非另有说明，否则数据反映了 CE 发现。CE/认知性深入访谈的平均年龄为 49.4 岁；绝大多数参与者使用眼镜来治疗老花眼。通过访谈确定了与眼镜治疗相关的四个主题：日常活动不便、眼睛/头部周围的负面身体感觉、局限性和日常生活的不利影响（例如，社会心理）。参与者最常报告与忘记眼镜和社会心理影响相关的不便（例如，感到/看起来更老）。还报告了眼睛疲劳和视力受限，无法看清不同距离的问题。在提供数据的有近视力眼镜的参与者中，三分之二的人表示对替代治疗感兴趣。此外，几乎四分之三的参与者将假设的眼药水列为首选或第二选择，而不是阅读眼镜、隐形眼镜、放大镜和手术。
本研究探讨了与老花眼共存和管理的经验，并确定了当前治疗方法的局限性和负面影响。药物开发（例如，眼药水）可能满足老花眼治疗领域的未满足需求。
